Page 3 - Association Code News Today

The UTS Students’ Association (UTSSA) last night voted to dismiss Education Officer Ellie Woodward five days before the end of her term.

UTSSA asks student activists to sign declaration amid continuing tensions A number of office-bearers have been asked to sign a declaration of good behaviour, or else face the removal of privileges or dismissal. May 6, 2021 In the University of Technology Sydney Students’ Association’s (UTSSA) latest crackdown on activist collectives, a number of office-bearers have been asked to sign a declaration of good behaviour. The declaration outlines that they will agree to follow the UTSSA by-laws, ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Gilead  and  Galapagos  announce  New  Commercialization  and  Development  Agreement  for  ... Galapagos NVDecember 15, 2020 GMT -- Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting -- -- Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications; Gilead to Re...

Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca® Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis in the U.S. Following FDA Type A Meeting — — Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis Plus Future Indications; Gilead to Receive Royalties on European Sales Starting in 2024 — — Galapagos to Assume Responsibility for Majority of Ongoing Clinical Trials; Gilead will Pay Ga...

Gilead Sciences, Inc.: Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca (Filgotinib) -- Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting -- -- Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications; Gilead to Receive Royalties on European Sales Starting in 2024 -- -- Galapagos to Assume Responsibility for Majority of ...

Share: -- Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting -- -- Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications; Gilead to Receive Royalties on European Sales Starting in 2024 -- -- Galapagos to Assume Responsibility for Majority of Ongoing Clinical Trials -- -- Gilead will Pay Galapagos €160 million to Support Ongoing Development and Accelerated Co...

Galapagos NV: Gilead and Galapagos announce New Commercialization and Development Agreement for Jyseleca (filgotinib) -- Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting -- -- Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications; Gilead to Receive Royalties on European Sales Starting in 2024 -- -- Galapagos to Assume Responsibility for Majority of Ongoing C...

Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib) -- Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting -- -- Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications; Gilead to Receive Royalties on European Sales Starting in 2024 -- -- Galapagos to Assume Responsibility for Majority of Ongoing Clini...

Message : Required fields -- Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting -- -- Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications; Gilead to Receive Royalties on European Sales Starting in 2024 -- -- Galapagos to Assume Responsibility for Majority of Ongoing Clinical Trials -- -- Gilead will Pay Galapagos €160 million to Support Ongoing Development...

Gilead  and  Galapagos  announce  New  Commercialization  and  Development  Agreement  for  Jyseleca®  (filgotinib)   -- Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting -- -- Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications; Gilead to Receive Royalties on European Sales Starting in 2024 -- -- Galapagos to Assume Responsibility for Majorit...